Why did Cigna's GAAP net income swing to a profit when adjusted results grew only modestly?

The swing reflects the absence of Q1 2024's $1.8 billion net investment loss, which was mostly non-recurring. In Q1 2025, net investment results were a small gain of $48 million. Adjusted income, which excludes investment gains and losses, amortization, and special items, rose only 3% to $1.84 billion, so most of the GAAP improvement comes from the prior-year loss not repeating rather than from stronger underlying operations.

What is driving the pressure in Cigna Healthcare's profitability?

Cigna Healthcare's MCR rose 230 basis points to 82.2%, mainly from expected higher stop-loss medical costs. The HCSC divestiture also closed later than planned, which kept the higher-cost Medicare businesses in the mix for longer. Adjusted pre-tax income for the segment fell 4% to $1.29 billion, and the segment's margin dropped to 8.9% from 10.1%.

How did the HCSC divestiture affect Cigna's customer base and financials?

Total customer relationships fell to 182.2 million from 186.8 million a year earlier, and medical customers dropped 6% to 18.0 million. Excluding the transaction, total customer relationships rose about 1% and medical customers were flat. Medicare Part D customers went to zero after the sale, and Cigna Healthcare's net medical costs payable fell to $4.37 billion from $4.86 billion at year-end 2024.

Is the raised 2025 guidance a meaningful improvement for investors?

The raise is modest. Adjusted EPS guidance moved up $0.10 to at least $29.60, and Cigna Healthcare's pre-tax outlook rose $25 million to at least $4.125 billion. Evernorth's outlook was unchanged at at least $7.2 billion. The guidance includes expected share repurchases and dividends, so part of the per-share lift reflects buybacks. Management does not reconcile forward adjusted results to GAAP net income because future investment results and special items are unpredictable.

What special items affected Q1 2025 results, and why do they matter?

Special items totaled $229 million after tax, including $164 million of integration and transaction costs and $163 million for a strategic optimization program, partly offset by a $115 million after-tax gain on the sale of businesses. These costs reduced GAAP net income but are excluded from adjusted results, so investors should review them as potentially recurring costs of ongoing portfolio changes and restructuring.

CI 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed May 2, 2025. Cited figures are marked; the original filing is the authoritative source.

The Cigna Group (CI) reported strong first quarter 2025 results on May 2, 2025, with total revenues rising 14% year over year to $65.5 billion^a and shareholders' net income of $1.3 billion, or $4.85 per diluted share, compared with a net loss of $0.97 per share a year earlier.

Adjusted income from operations was $1.8 billion^b, or $6.74 per share, up from $6.47 in the prior-year quarter. Growth was driven by Evernorth Health Services, where adjusted revenues rose 16%, largely from specialty pharmacy growth and new and existing client relationships. Cigna Healthcare's adjusted pre-tax income fell 4% as its medical care ratio rose to 82.2% from 79.9%, reflecting higher stop-loss medical costs and the timing of the Medicare divestiture to HCSC, which closed March 19, 2025.

Management raised its full-year 2025 adjusted income from operations outlook to at least $29.60^c per share, up $0.10, and raised the Cigna Healthcare pre-tax outlook by $25 million to at least $4.125 billion. Evernorth's pre-tax outlook was held at at least $7.2 billion. The guidance implies a Cigna Healthcare MCR of 83.2% to 84.2%.

The company repurchased 8.2 million shares for about $2.6 billion^d year to date through May 1, 2025, and its share count fell to roughly 270 million from 284 million a year earlier. Investors should weigh the headline revenue and earnings growth against the Cigna Healthcare margin compression and the reduction in medical customers, which fell 6% to 18.0 million largely because of the HCSC transaction. The GAAP net income figure was also boosted by a gain on the sale of businesses and reflects large special items, including $215 million for a strategic optimization program and $216 million in integration and transaction costs, which are excluded from adjusted results.

02—Key points

Key Highlights

Total revenues rose 14% to $65.5 billion in Q1 2025, driven by Evernorth's specialty pharmacy growth and client expansion.
GAAP shareholders' net income of $1.3 billion ($4.85 per share) swung from a $0.3 billion loss ($0.97 per share) a year earlier.
Adjusted income from operations was $1.84 billion ($6.74 per share), up from $6.47 per share in Q1 2024.
Full-year 2025 adjusted EPS outlook was raised to at least $29.60, up $0.10, and Cigna Healthcare's pre-tax outlook was raised $25 million to at least $4.125 billion.
Cigna Healthcare MCR rose to 82.2% from 79.9%, reflecting higher stop-loss costs and the Medicare divestiture timing; the full-year MCR is guided to 83.2%-84.2%.
Evernorth adjusted revenues grew 16%, but pre-tax margin compressed to 2.7% from 2.9% as strategic investments weighed on profit.
The company repurchased 8.2 million shares for about $2.6 billion year to date and completed the Medicare business divestiture to HCSC on March 19, 2025.

03—Questions

Frequently Asked Questions

Why did Cigna's GAAP net income swing to a profit when adjusted results grew only modestly?
The swing reflects the absence of Q1 2024's $1.8 billion net investment loss, which was mostly non-recurring. In Q1 2025, net investment results were a small gain of $48 million. Adjusted income, which excludes investment gains and losses, amortization, and special items, rose only 3% to $1.84 billion, so most of the GAAP improvement comes from the prior-year loss not repeating rather than from stronger underlying operations.
What is driving the pressure in Cigna Healthcare's profitability?
Cigna Healthcare's MCR rose 230 basis points to 82.2%, mainly from expected higher stop-loss medical costs. The HCSC divestiture also closed later than planned, which kept the higher-cost Medicare businesses in the mix for longer. Adjusted pre-tax income for the segment fell 4% to $1.29 billion, and the segment's margin dropped to 8.9% from 10.1%.
How did the HCSC divestiture affect Cigna's customer base and financials?
Total customer relationships fell to 182.2 million from 186.8 million a year earlier, and medical customers dropped 6% to 18.0 million. Excluding the transaction, total customer relationships rose about 1% and medical customers were flat. Medicare Part D customers went to zero after the sale, and Cigna Healthcare's net medical costs payable fell to $4.37 billion from $4.86 billion at year-end 2024.
Is the raised 2025 guidance a meaningful improvement for investors?
The raise is modest. Adjusted EPS guidance moved up $0.10 to at least $29.60, and Cigna Healthcare's pre-tax outlook rose $25 million to at least $4.125 billion. Evernorth's outlook was unchanged at at least $7.2 billion. The guidance includes expected share repurchases and dividends, so part of the per-share lift reflects buybacks. Management does not reconcile forward adjusted results to GAAP net income because future investment results and special items are unpredictable.
What special items affected Q1 2025 results, and why do they matter?
Special items totaled $229 million after tax, including $164 million of integration and transaction costs and $163 million for a strategic optimization program, partly offset by a $115 million after-tax gain on the sale of businesses. These costs reduced GAAP net income but are excluded from adjusted results, so investors should review them as potentially recurring costs of ongoing portfolio changes and restructuring.

04—Continue

← View all 8-K filings